Safety and immunogenicity of three-dose vaccination with the Pfizer/BioNtech SARS-CoV-2 mRNA vaccine
A recent article published in the Med journal reported that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccinations enhance the SARS-CoV-2 Omicron sublineage ...
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 600 million confirmed cases and 6.5 million deaths worldwide. mRNA-based ...
While the currently available coronavirus disease 2019 (COVID-19) vaccines have shown great efficacy in reducing the risk of hospitalization upon infection with severe acute respiratory syndrome ...
In Cuba, the routine immunization (RI) schedule for polio consists of two doses of fIPV administered at 4 and 8 months of age administered intradermally with N/S. However, ID administration with N/S ...
The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the ...
Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...
Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results